Forte Biosciences Inc

Forte Biosciences Inc(FBRX)のニュースとイベント

$76.990

+0.023 (+0.03%)終値時点

FBRX のニュース

FBRX のイベント

7/28 08:00

Wedbush Raises Argenx Price Target to $1,050 and Acquires Forte

Wedbush raised the firm's price target on Argenx (ARGX) to $1,050 from $1,000 and keeps an Outperform rating on the shares. The firm notes the company will acquire Forte Biosciences (FBRX) for $77/share in cash, adding FB102, a first-in-class anti-CD122 antibody, to its growing immunology pipeline. The transaction follows Argenx's strategic investment in Forte's April financing at $26.27/share and reflects management's continued strategy of selectively acquiring differentiated immunology assets with broad pipeline-in-a-product potential. The acquisition is supported by encouraging early proof-of-concept across two autoimmune diseases, Wedbush adds.

7/27 16:30

Dow Rises, Nasdaq Falls as Market Focuses on Economic Data

The major averages had a mixed day, with the Dow and the S&P 500 higher and Nasdaq in decline amid weakness in tech stocks as the market has reacted positively to easing geopolitical tensions and a steep decline in oil prices.Investor attention is focused on a week that includes the Federal Reserve's July policy meeting, second-quarter GDP data, the June personal consumption expenditures price index, and earnings from four of the "Magnificent Seven" companies. The combination of major economic data and heavyweight earnings is expected to drive market direction through the end of the week.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:Appleis lobbying the Trump administration to let it use Chinese memory chips, while U.S. supplier Micronis pushing to block the move,ArgenxForte Biosciencesfor $77 per share in cashNaver, Nvidia, and Brookfieldannounced a proposed expansion of, with planned investments that will grow the initial Nvidia DSX AI factory deployment to 200 megawattsMeanwhile, Nvidia is in talks to provide a $250B backstop for OpenAI,Baker Hughesreported2. WALL STREET CALLS:JefferiesFordand General Motorsto BuyRivianto Overweight at Piper SandlerStellantisto Underweight from Overweight at Piper SandlerJPMorganCheck Pointon weaker competitive positionWall Streetcoverage of Bending Spoonswith a mix of Buy and Hold-equivalent ratings3. AROUND THE WEB:Fordhas entered the competition to build the U.S. Army's next-generation tactical truck, WSJ reportsA Chinese state-backed company has begun manufacturing immersion deep ultraviolet lithography machines, a key type of equipment used by chipmakers like TSMCin producing chips, The Information saysParamount Skydanceand Warner Bros. Discoveryremain in limbo as their $81B merger faces an antitrust review that could delay the deal into 2027, limiting strategic moves while the companies focus on legal proceedings and competitors continue to expand, WSJ saysUniCreditCEO Andrea Orcel sees room for an agreement over the bank's proposed takeover of Commerzbank, signaling confidence discussions with the government and stakeholders could lead to a deal, Bloomberg saysTrip.comhas been fined $765M by Chinese regulators after it was concluded that the company abused its market dominance, Bloomberg reports4. MOVERS:D-Wave Quantumgained afterwith AT&TOmerosincreased after AstraZenecareportedof ultomirisGenius Sportswas higher in New York after Goldman Sachscoverage of the stock with a Buy ratingCapricor Therapeuticswas lower after the FDAMapLight Therapeuticsfell after announcing results from its5. EARNINGS/GUIDANCE:AstraZenecaand reaffirmed its guidance for FY26, with CEO Pascal Soriot commenting on "strong performance and continued pipeline delivery" in the first halfEnsign Groupand raised its outlook for FY26Bank of Marin, with EPS beating consensusBank of Hawaii, with CEO Jim Polk calling them "solid"Sierra Bancorp, with EPS missing consensusINDEXES:The Dow rose 262.83, or 0.51%, to 52,210.08, the Nasdaq lost 43.74, or 0.18%, to 24,932.08, and the S&P 500 advanced 1.20, or 0.02%, to 7,413.18.

7/27 12:30

Argenx Acquires Forte for $77/Share, H.C. Wainwright Bullish on First Tracks

After Argenx (ARGX) announced a deal to acquire Forte (FBRX) for a price of $77 per share, a 43% premium to Friday's share price and a total equity value of $2.2B, H.C. Wainwright said the firm views the Forte acquisition as "highly relevant" for First Tracks Biotherapeutics (TRAX). Forte's anti-CD122 antibody, FB102, is a direct competitor for First Tracks' ANB033 asset, which is in development for celiac disease and eosinophilic esophagitis, notes the analyst, who believes the rival acquisition news "bodes well for ANB033 and makes First Tracks a potential acquisition target, assuming Phase 1b CeD data are positive." The firm has a Buy rating on First Tracks and says it is evaluating its estimates and valuation assumptions based on today's news.

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

無料で始める